JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 10.72 Billion JPY | 43.46% |
| 2022 | 6.97 Billion JPY | -66.76% |
| 2021 | 21.88 Billion JPY | 115.07% |
| 2020 | 10.18 Billion JPY | 120.3% |
| 2019 | 4.67 Billion JPY | -25.92% |
| 2018 | 6.31 Billion JPY | 22.91% |
| 2017 | 5.16 Billion JPY | 32.21% |
| 2016 | 3.96 Billion JPY | 5.78% |
| 2015 | 3.89 Billion JPY | 3.98% |
| 2014 | 3.72 Billion JPY | 26.45% |
| 2013 | 2.83 Billion JPY | 29.77% |
| 2012 | 2.09 Billion JPY | 0.99% |
| 2011 | 2.1 Billion JPY | -7.78% |
| 2010 | 2.3 Billion JPY | -12.21% |
| 2009 | 2.39 Billion JPY | 91.05% |
| 2008 | 1.31 Billion JPY | 20.73% |
| 2007 | 1.07 Billion JPY | 630.68% |
| 2006 | 33 Million JPY | -57.77% |
| 2005 | 375.62 Million JPY | 128.53% |
| 2004 | -1.33 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -163 Million JPY | 114.38% |
| 2024 Q1 | 316 Million JPY | 272.86% |
| 2023 Q3 | 1.84 Billion JPY | -62.2% |
| 2023 Q4 | 649 Million JPY | -64.86% |
| 2023 FY | - JPY | 43.46% |
| 2023 Q1 | 2.27 Billion JPY | 1551.45% |
| 2023 Q2 | 4.88 Billion JPY | 114.39% |
| 2022 Q4 | 138 Million JPY | -96.32% |
| 2022 FY | - JPY | -66.76% |
| 2022 Q1 | 2.09 Billion JPY | 16.28% |
| 2022 Q2 | -503 Million JPY | -124.03% |
| 2022 Q3 | 3.75 Billion JPY | 846.32% |
| 2021 Q4 | 1.8 Billion JPY | -64.03% |
| 2021 Q3 | 5 Billion JPY | -53.46% |
| 2021 FY | - JPY | 115.07% |
| 2021 Q1 | 2.99 Billion JPY | -33.28% |
| 2021 Q2 | 10.75 Billion JPY | 258.55% |
| 2020 Q3 | 2.7 Billion JPY | 443.37% |
| 2020 Q4 | 4.49 Billion JPY | 66.11% |
| 2020 FY | - JPY | 120.3% |
| 2020 Q1 | 871 Million JPY | -22.78% |
| 2020 Q2 | 498 Million JPY | -42.82% |
| 2019 Q3 | 1.19 Billion JPY | 129.81% |
| 2019 Q2 | 520 Million JPY | 10.17% |
| 2019 Q1 | 472 Million JPY | -80.78% |
| 2019 FY | - JPY | -25.92% |
| 2019 Q4 | 1.12 Billion JPY | -5.61% |
| 2018 FY | - JPY | 22.91% |
| 2018 Q2 | 1.43 Billion JPY | 147.76% |
| 2018 Q3 | 595 Million JPY | -58.59% |
| 2018 Q4 | 2.45 Billion JPY | 312.77% |
| 2018 Q1 | 580 Million JPY | 23.67% |
| 2017 Q2 | 1.84 Billion JPY | 190.87% |
| 2017 FY | - JPY | 32.21% |
| 2017 Q4 | 469 Million JPY | -46.89% |
| 2017 Q3 | 883 Million JPY | -52.19% |
| 2017 Q1 | 635 Million JPY | 18.43% |
| 2016 Q2 | 996.25 Million JPY | 161.02% |
| 2016 Q1 | 381.67 Million JPY | 55.86% |
| 2016 FY | - JPY | 5.78% |
| 2016 Q4 | 536.2 Million JPY | -8.13% |
| 2016 Q3 | 583.68 Million JPY | -41.41% |
| 2015 Q1 | 574.8 Million JPY | -36.6% |
| 2015 Q4 | 244.87 Million JPY | -63.37% |
| 2015 FY | - JPY | 3.98% |
| 2015 Q3 | 668.46 Million JPY | -19.83% |
| 2015 Q2 | 833.82 Million JPY | 45.06% |
| 2014 FY | - JPY | 26.45% |
| 2014 Q2 | 238.23 Million JPY | -20.71% |
| 2014 Q3 | 789.02 Million JPY | 231.2% |
| 2014 Q4 | 906.64 Million JPY | 14.91% |
| 2014 Q1 | 300.44 Million JPY | 53.19% |
| 2013 Q3 | 815.37 Million JPY | 152.61% |
| 2013 Q4 | 196.12 Million JPY | -75.95% |
| 2013 Q2 | 322.77 Million JPY | -17.27% |
| 2013 Q1 | 390.15 Million JPY | -8.55% |
| 2013 FY | - JPY | 29.77% |
| 2012 Q2 | 277.96 Million JPY | 123.46% |
| 2012 Q4 | 426.6 Million JPY | 12.99% |
| 2012 FY | - JPY | 0.99% |
| 2012 Q1 | 124.39 Million JPY | 30.73% |
| 2012 Q3 | 377.57 Million JPY | 35.83% |
| 2011 Q3 | 415.12 Million JPY | 4.18% |
| 2011 Q2 | 398.47 Million JPY | 158.4% |
| 2011 Q1 | 154.2 Million JPY | -49.12% |
| 2011 FY | - JPY | -7.78% |
| 2011 Q4 | 95.15 Million JPY | -77.08% |
| 2010 Q1 | 1.1 Billion JPY | 119.34% |
| 2010 Q4 | 303.1 Million JPY | -45.18% |
| 2010 FY | - JPY | -12.21% |
| 2010 Q3 | 552.9 Million JPY | 45.06% |
| 2010 Q2 | 381.14 Million JPY | -65.66% |
| 2009 Q3 | 1.42 Billion JPY | 694.28% |
| 2009 Q4 | 506.02 Million JPY | -64.36% |
| 2009 FY | - JPY | 91.05% |
| 2009 Q2 | 178.77 Million JPY | -68.57% |
| 2009 Q1 | 568.79 Million JPY | 4.12% |
| 2008 Q4 | 546.29 Million JPY | -32.28% |
| 2008 FY | - JPY | 20.73% |
| 2008 Q3 | 806.66 Million JPY | 794.47% |
| 2008 Q2 | -116.15 Million JPY | 0.0% |
| 2007 FY | - JPY | 630.68% |
| 2006 FY | - JPY | -57.77% |
| 2005 FY | - JPY | 128.53% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 117.59 Billion JPY | 90.876% |
| Astellas Pharma Inc. | 195.34 Billion JPY | 94.508% |
| Chugai Pharmaceutical Co., Ltd. | 470.91 Billion JPY | 97.722% |
| Ono Pharmaceutical Co., Ltd. | 178.43 Billion JPY | 93.987% |
| Santen Pharmaceutical Co., Ltd. | 56.45 Billion JPY | 80.996% |
| Daiichi Sankyo Company, Limited | 305.45 Billion JPY | 96.488% |
| Otsuka Holdings Co., Ltd. | 224.19 Billion JPY | 95.215% |
| Perseus Proteomics Inc. | -892 Million JPY | 1302.803% |